575 related articles for article (PubMed ID: 27350037)
1. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
2. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer.
Shi H; Jiang J; Ji J; Shi M; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Lett; 2014 Jul; 349(2):128-35. PubMed ID: 24746899
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
Yanagisawa M; Fujimoto-Ouchi K; Yorozu K; Yamashita Y; Mori K
Oncol Rep; 2009 Aug; 22(2):241-7. PubMed ID: 19578762
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis.
Yuan F; Shi H; Ji J; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
Oncol Rep; 2015 Apr; 33(4):1753-62. PubMed ID: 25634241
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
[TBL] [Abstract][Full Text] [Related]
7. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
[TBL] [Abstract][Full Text] [Related]
8. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.
Pineda E; Salud A; Vila-Navarro E; Safont MJ; Llorente B; Aparicio J; Vera R; Escudero P; Casado E; Bosch C; Bohn U; Pérez-Carrión R; Carmona A; Ayuso JR; Ripollés T; Bouzas R; Gironella M; García-Albéniz X; Feliu J; Maurel J
Tumour Biol; 2017 Jun; 39(6):1010428317705509. PubMed ID: 28621236
[TBL] [Abstract][Full Text] [Related]
9. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
11. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
[TBL] [Abstract][Full Text] [Related]
12. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
Mésange P; Poindessous V; Sabbah M; Escargueil AE; de Gramont A; Larsen AK
Oncotarget; 2014 Jul; 5(13):4709-21. PubMed ID: 25015210
[TBL] [Abstract][Full Text] [Related]
14. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model.
Mueller T; Freystein J; Lucas H; Schmoll HJ
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394786
[TBL] [Abstract][Full Text] [Related]
16. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
[TBL] [Abstract][Full Text] [Related]
17. Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy.
Cheng L; Liu W; Zhong C; Ni P; Ni S; Wang Q; Zhang Q; Zhang J; Liu J; Xu M; Yao X; Cen X; Wang G; Jiang C; Zhou F
J Ethnopharmacol; 2021 Apr; 270():113770. PubMed ID: 33388426
[TBL] [Abstract][Full Text] [Related]
18. Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update.
Marien KM; Croons V; Martinet W; De Loof H; Ung C; Waelput W; Scherer SJ; Kockx MM; De Meyer GR
Expert Rev Mol Diagn; 2015 Mar; 15(3):399-414. PubMed ID: 25585649
[TBL] [Abstract][Full Text] [Related]
19. FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA.
Wang S; Xiao Z; Hong Z; Jiao H; Zhu S; Zhao Y; Bi J; Qiu J; Zhang D; Yan J; Zhang L; Huang C; Li T; Liang L; Liao W; Ye Y; Ding Y
Cancer Lett; 2018 Dec; 439():78-90. PubMed ID: 30253191
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway.
Liu W; Zhang J; Yao X; Jiang C; Ni P; Cheng L; Liu J; Ni S; Chen Q; Li Q; Zhou K; Wang G; Zhou F
Cancer Sci; 2018 Oct; 109(10):3294-3304. PubMed ID: 30151975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
